Dato-DXd showed a 43% reduction in disease progression risk and a 21% reduction in death risk compared to chemotherapy in TNBC patients ineligible for immunotherapy. The TROPION-Breast02 trial ...

Data demonstrated that vepdegestrant maintained patients’ quality of life for statistically significantly longer and delayed worsening of overall health, daily functioning, and symptoms, including ...

Data demonstrated that vepdegestrant maintained patients’ quality of life for statistically significantly longer and delayed worsening of ...

The impact of digital transformation, increased regulation, rising costs, bouncing tariffs and volatile geopolitics are just some of the big issues keeping Australian business leaders up at night.

The perioperative enfortumab vedotin plus pembrolizumab (EV-P) substantially increased the frequency of adverse events (AEs), ...

As global food prices continue to rise, evidence shows that perishable goods are the overwhelming driver behind the increase.

Falling Fed rates and favorable policies make XLV a strong healthcare ETF pick. Read here for an analysis of its growth ...

Trump, in an effort to lower drug costs for U.S. patients who pay far more than in other wealthy nations, has so far struck ...

Alectinib showed a 22% reduction in death risk compared to crizotinib in advanced ALK-positive NSCLC, with a median OS of 81.1 months versus 54.2 months. Significant OS benefits were observed in ...

Merck MRK is facing persistent challenges for its second-largest product, Gardasil, which is a vaccine for the prevention of ...

The FDA announced the first nine recipients of the Commissioner’s National Priority Review vouchers, a program offering an ...

This sustained sell-off has wiped out approximately $18 billion in market capitalization, leaving its current value at around ...